for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

GlaxoSmithKline plc

GSK.L

Latest Trade

1,424.60GBp

Change

3.80(+0.27%)

Volume

5,154,012

Today's Range

1,422.00

 - 

1,436.20

52 Week Range

1,190.80

 - 

1,528.80

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
1,420.80
Open
1,428.00
Volume
5,154,012
3M AVG Volume
126.30
Today's High
1,436.20
Today's Low
1,422.00
52 Week High
1,528.80
52 Week Low
1,190.80
Shares Out (MIL)
5,031.74
Market Cap (MIL)
71,491.02
Forward P/E
14.00
Dividend (Yield %)
5.63

Next Event

Q3 2021 GlaxoSmithKline PLC Earnings Release

Latest Developments

More

Viome Life Sciences Announces Expansion Of Collaboration With GSK

GSK Says 'Far Advanced' With Plan For Separation Of Consumer Unit

GlaxoSmithKline's Consumer Unit Is Drawing Interest From Private Equity Firms - Bloomberg News

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About GlaxoSmithKline plc

GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.

Industry

Biotechnology & Drugs

Contact Info

G S K House, 980 Great West Road

TW8 9GS

United Kingdom

+44.20.80475000

https://www.gsk.com/

Executive Leadership

Jonathan Richard Symonds

Independent Non-Executive Chairman of the Board

Emma N. Walmsley

Chief Executive Officer, Executive Director

Iain James Mackay

Chief Financial Officer, Executive Director

Roger G. Connor

President - Global Vaccines

Brian McNamara

Chief Executive Officer - GSK Consumer Healthcare

Key Stats

2.59 mean rating - 29 analysts
Sell
Hold
Buy
Revenue (MM, GBP)

2018

30.8K

2019

33.8K

2020

34.1K

2021(E)

33.5K
EPS (GBp)

2018

119.400

2019

123.900

2020

115.900

2021(E)

101.454
Price To Earnings (TTM)
16.34
Price To Sales (TTM)
2.17
Price To Book (MRQ)
4.65
Price To Cash Flow (TTM)
11.65
Total Debt To Equity (MRQ)
165.72
LT Debt To Equity (MRQ)
132.94
Return on Investment (TTM)
9.78
Return on Equity (TTM)
6.27

Latest News

Latest News

BRIEF-GSK Announces 50 Mln Stg Investment In Renewable Energy And Carbon Reduction

* GSK- ANNOUNCES £50M INVESTMENT IN RENEWABLE ENERGY AND CARBON REDUCTION AT MAJOR UK AND US MANUFACTURING SITES Source text for Eikon: Further company coverage:

BRIEF-Viome Life Sciences Announces Expansion Of Collaboration With GSK

* VIOME LIFE SCIENCES ANNOUNCES EXPANSION OF COLLABORATION WITH GSK INTO NEW THERAPEUTIC INTERVENTIONS FOR CANCERS AND AUTOIMMUNE DISEASES Source text for Eikon: Further company coverage:

Factbox-Front runners in development of antibody drugs against COVID-19

AstraZeneca, Eli Lilly, Regeneron and GlaxoSmithKline are among the biggest players to have developed COVID-19 treatments using a class of drugs called monoclonal antibodies.

GSK on track with consumer split as buyout report boosts shares

GlaxoSmithKline is "firmly on track" to spin off its consumer health business next year, the British drugmaker said on Tuesday, after Bloomberg News reported the unit could attract bids from private equity firms such as Advent, CVC and KKR.

BRIEF-GSK Says 'Far Advanced' With Plan For Separation Of Consumer Unit

* GSK SAYS 'GSK IS FAR ADVANCED WITH ITS PLAN FOR THE SEPARATION OF CONSUMER HEALTHCARE'

BRIEF-GlaxoSmithKline's Consumer Unit Is Drawing Interest From Private Equity Firms - Bloomberg News

* PRIVATE EQUITY FIRMS CIRCLE GLAXOSMITHKLINE’S $54 BILLION CONSUMER ARM - BLOOMBERG NEWS

GSK to cement split with two new headquarters

GlaxoSmithKline on Monday laid out plans for a new, 120 million pound ($164 million) headquarters for its soon-to-be-independent consumer healthcare business and also said its remaining pharmaceuticals and vaccines staff will relocate.

Govt to control distribution of GSK/Vir COVID-19 antibody in U.S. - FDA

The U.S. Food and Drug Administration said on Friday distribution of GlaxoSmithKline and Vir Biotechnology's antibody treatment for COVID-19 would be controlled by the government.

African Union to start talks with WHO on malaria vaccine rollout

Africa will start talks with the World Health Organization about getting the first approved malaria vaccine to the continent as soon as possible, the African Union's top health official said on Thursday, amid calls for funding for drugs beyond COVID-19.

BRIEF-GSK Welcomes WHO Recommendation For Broad Roll-Out Of Its RTS,S/AS01e (RTS,S) Malaria Vaccine

* GSK WELCOMES WHO RECOMMENDATION FOR BROAD ROLL-OUT OF ITS RTS,S/AS01E (RTS,S) MALARIA VACCINE Source text for Eikon: Further company coverage:

GSK to supply 10,000 doses of COVID-19 drug to Canada

London-based drugmaker GlaxoSmithKline PLC said on Monday it signed a deal to supply 10,000 doses of its COVID-19 monoclonal antibody therapy to the Canadian government.

BRIEF-Medicago, GSK To Launch Trials Of COVID-19 Vaccine Candidate In Japan

* MEDICAGO TO LAUNCH CLINICAL TRIALS FOR COVID-19 VACCINE CANDIDATE WITH GSK'S PANDEMIC ADJUVANT IN JAPAN

Merck KGaA, GSK end partnership on former cancer drug hopeful

Germany's Merck KGaA and Britain's GlaxoSmithKline on Thursday ended their collaboration on cancer treatment bintrafusp alfa, once seen as one of Merck's most promising experimental drugs.

BRIEF-GSK Says FDA Grants Priority Review To Viiv's NDA For Cabotegravir Long-Acting For HIV Prevention

* PRESS RELEASE: FDA GRANTS PRIORITY REVIEW TO VIIV HEALTHCARE’S NEW DRUG APPLICATION FOR CABOTEGRAVIR LONG-ACTING FOR PREVENTION OF HIV

BRIEF-GSK's ViiV Healthcare To Develop Next-Gen HIV Treatments With Shionogi

* VIIV HEALTHCARE ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH SHIONOGI TO DEVELOP THIRD-GENERATION HIV INTEGRASE INHIBITOR WITH POTENTIAL FOR ULTRA LONG-ACTING DOSING INTERVALS

Activist investor Bluebell takes stake in GSK

Activist investor Bluebell Capital Partners has taken a stake worth about 10 million euros in British pharmaceuticals group GlaxoSmithKline in efforts to shake up top management, a Financial Times report https://www.ft.com/content/539c077d-6ac2-4e79-9e0f-8080a31c5530 said...

Activist investor Bluebell takes stake in GSK - FT

Activist investor Bluebell Capital Partners has taken a small stake in British pharmaceuticals group GlaxoSmithKline in efforts to shake up top management, a Financial Times report https://www.ft.com/content/539c077d-6ac2-4e79-9e0f-8080a31c5530 said on Wednesday.

BRIEF-Activist Bluebell Takes Stake In GlaxoSmithKline To Push For Change At Top - FT

* ACTIVIST BLUEBELL TAKES STAKE IN GLAXOSMITHKLINE TO PUSH FOR CHANGE AT TOP - FT

BRIEF-GSK Announces £50m Investment In Renewable Energy And Carbon Reduction

* PRESS RELEASE: GSK ANNOUNCES MAJOR RENEWABLE ENERGY INVESTMENT AND LOW CARBON INHALER PROGRAMME ALONGSIDE LIFE SCIENCES SECTOR RACE TO ZERO ‘BREAKTHROUGH’ AT NYC CLIMATE WEEK

S. Korean COVID-19 vaccine in late-stage test against AstraZeneca shot

South Korea's SK Bioscience and Britain's GSK said on Tuesday the drugmakers had begun a late-stage trial of their COVID-19 vaccine candidate against AstraZeneca's approved shot, the second study of its kind globally.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up